Table 1.

Baseline Patient Demographics and Clinical Characteristics

	CP-870,893 Dose Cohort
	0.1 mg/kg (N=3)		0.2 mg/kg (N=6)		MTD Expansion 0.2 mg/kg (N=13)
Characteristic	No	%	No.	%	No.	%
Age, years
Median		59			59
Range		57-72			40-81
Sex
Male	2	67%	3	50%	9	69%
Female	1	33%	3	50%	4	31%
Race/ethnicity
White	0	0%	5	83%	11	84%
Black	3	100%	1	17%	1	8%
Asian	0	0%	0	0%	1	8%
ECOG PS
0	2	67%	5	83%	2	15%
1	1	33%	1	17%	11	85%
Extent of Disease
Locally advanced	0	0%	0	0%	2	15%
Metastatic	3	100%	6	100%	11	85%
Location of Primary
Head	2	67%	2	33%	4	31%
Body or Tail	1	33%	2	33%	9	69%
Not reported	0	0%	2	33%	0	0%
Site of Metastases
Liver	3	100%	5	83%	10	77%
Lung	0	0%	2	33%	0	0%
Peritoneal	0	0%	0	0%	3	23%
Skeleton	0	0%	2	33%	0	0%
Other	0	0%	0	0%	1	8%
Prior Radiation Therapies
No	3	100%	6	100%	11	84%
Yes	0	0%	0	0%	1	8%
Not Reported	0	0%	0	0%	1	8%

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; IVTD, maximum tolerated dose